The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2019

Filed:

Jun. 01, 2018
Applicants:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Emory University, Atlanta, GA (US);

Inventors:

Gordon J. Freeman, Brookline, MA (US);

Rafi Ahmed, Atlanta, GA (US);

Timothy D. Jones, Cambridgeshire, GB;

Francis J. Carr, Aberdeenshire, GB;

James P. Gregson, Essex, GB;

Assignees:

EMORY UNIVERSITY, Atlanta, GA (US);

DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/13 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); Y02A 50/41 (2018.01); Y02A 50/412 (2018.01);
Abstract

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.


Find Patent Forward Citations

Loading…